Latest Inspiremd Inc (NSPR) Headlines Inspire
Post# of 52
Posted On: 03/10/2014 8:06:55 PM
Latest Inspiremd Inc (NSPR) Headlines
InspireMD to Present at the 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that its CEO, Alan Milinazzo, will be presenting at the 26th Annual ROTH Conference at the Ritz Carlton, Laguna Niguel in Dana Point, CA. The Company will present at 5:00 p.m. PT on Tuesday, March 11, 2014.
InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that its CEO, Alan Milinazzo, will be presenting at the Cowen & Company 34th Annual Health Care Conference at The Boston Marriott Copley Place, in Boston. The Company will present at 9:20 a.m. EST on Wednesday, March 5, 2014.
InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013
PR Newswire - Wed Feb 26, 3:05PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced financial and operating results for the quarter and the six month period ended December 31, 2013.
InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014
PR Newswire - Tue Feb 18, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the six month period ended December 31, 2013 on February 26, 2014.
InspireMD Reports Successful Implantation of the New CGuard(TM) Carotid Embolic System with MicroNet(TM) Technology
PR Newswire - Wed Feb 05, 8:23AM CST
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems, today announced that its new CGuard(TM) carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17th Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on February 1, 2014.
3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion by 2019
M2 - Mon Jan 27, 9:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rr9nj/3_catalysts_to) has announced the addition of the "3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019, despite the current downward trend in the US, the largest market, and declining selling prices globally. Increasing PCI (percutaneous coronary intervention) procedures triggered by the rising prevalence of CAD (coronary artery disease), novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players - Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by a team of sector analysts who used rigorous primary and secondary research and robust analytical models to provide strategic insight and to forecast for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Data at global, continents, economic zones, and country level: - Market size of coronary stents in terms - value and volume (2005-2019) for BMS, DES and Bioabsorbables (Bioresorbable - BVS) - Market growth rates (2005-2019) - Average prices of various stents in all the covered geographies (2005-2019) - Number of PCI procedures - Analytical comparison between different continents and economic regions - Market dynamics - market trends, drivers, restrains, issues, competitive landscape - Detailed pipeline and clinical studies - Product approval status - major geographies - Industry consolidation, partnerships, product launches, approvals and recalls - Detailed company profiles of around 70 companies from different levels of value chain Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10.Coronary Stents - Market Drivers and Restrains 11.Overview: Market trends 12.Approvals Driving the Growth 13. Market Data 14.Company Profiles 15.Recent Events 16.Appendix 17. Research Methodology 18. Disclaimer Companies Mentioned Include: - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Terumo Medical Corporation - Translumina - Tryton Medical - Vascular Concepts For more information visit http://www.researchandmarkets.com/research/3r...talysts_to
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 22, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
InspireMD to Present at the 24th Annual Oppenheimer & Co. Healthcare Conference in New York City on December 11th
PR Newswire - Tue Dec 03, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that its CEO, Alan Milinazzo will be presenting at the 24th Annual Oppenheimer & Co. Healthcare Conference at the Crowne Plaza Hotel in New York City. The Company will present at 2:45 p.m. ET on Wednesday, December 11, 2013.
InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
PR Newswire - Mon Dec 02, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced the appointment of Rick Olson as Vice President of Global Sales Operations based in the United Kingdom.
InspireMD Announces Upcoming Investor Event in Israel
PR Newswire - Tue Nov 19, 8:13AM CST
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it will host an investor event at the Dan Tel Aviv Hotel in Tel Aviv, Israel on December 2, 2013 at 5:00 p.m. local time.
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
PR Newswire - Mon Nov 11, 3:01PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for the quarter ended September 30, 2013.
InspireMD to Report Financial Results for Quarter Ending September 30, 2013 on Monday, November 11, 2013
PR Newswire - Mon Nov 04, 7:00AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the quarter ended September 30, 2013 on Monday, November 11, 2013.
InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
PR Newswire - Tue Oct 29, 3:23PM CDT
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced new 12-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients. Results from the trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco earlier today.
InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
PR Newswire - Mon Oct 28, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will host a conference call to discuss its MASTER trial 12-month follow up data on October 30, 2013 at 8:30 a.m. ET / 5:30 a.m. PT.
Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
PR Newswire - Fri Oct 25, 8:14AM CDT
Today Empire Asset Management Company, a FINRA member (CRD 143007), initiated coverage of INSPIRE MD (NYSE MKT: NSPR) with a Buy rating and 12 month price target of $9.00.
InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
PR Newswire - Thu Oct 24, 8:15AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced that it has secured $10 million in venture debt financing to support expanding its ability to execute on emerging clinical research and product development efforts. The Company also announced it has adopted a stockholder rights plan effective for a one year period.
InspireMD Files At-the-Market Offering and Shelf Registration Statement
PR Newswire - Thu Oct 24, 8:08AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it has filed a $75 million shelf registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC"). Once declared effective by the SEC, the shelf registration statement would permit the Company to sell, from time to time over the next three years, up to $75 million in aggregate value of its common stock, preferred stock and/or warrants, either individually or in units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
PR Newswire - Wed Oct 23, 1:43PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will ring the Opening Bell at the New York Stock Exchange on Thursday, October 24, 2013 at 9:30 a.m. ET.
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
PR Newswire - Tue Sep 17, 3:05PM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013.
InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
PR Newswire - Mon Sep 16, 7:30AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced the appointment of David Blossom as Vice President of Global Marketing and Strategy. Blossom will be based in Boston.
InspireMD to Present at the 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that its CEO, Alan Milinazzo, will be presenting at the 26th Annual ROTH Conference at the Ritz Carlton, Laguna Niguel in Dana Point, CA. The Company will present at 5:00 p.m. PT on Tuesday, March 11, 2014.
InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that its CEO, Alan Milinazzo, will be presenting at the Cowen & Company 34th Annual Health Care Conference at The Boston Marriott Copley Place, in Boston. The Company will present at 9:20 a.m. EST on Wednesday, March 5, 2014.
InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013
PR Newswire - Wed Feb 26, 3:05PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced financial and operating results for the quarter and the six month period ended December 31, 2013.
InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014
PR Newswire - Tue Feb 18, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the six month period ended December 31, 2013 on February 26, 2014.
InspireMD Reports Successful Implantation of the New CGuard(TM) Carotid Embolic System with MicroNet(TM) Technology
PR Newswire - Wed Feb 05, 8:23AM CST
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems, today announced that its new CGuard(TM) carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17th Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on February 1, 2014.
3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion by 2019
M2 - Mon Jan 27, 9:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rr9nj/3_catalysts_to) has announced the addition of the "3 Catalysts To Catapult Global Coronary Stent Market To $13 Billion" report to their offering. The global coronary stent market is expected to be over $13 billion by 2019, despite the current downward trend in the US, the largest market, and declining selling prices globally. Increasing PCI (percutaneous coronary intervention) procedures triggered by the rising prevalence of CAD (coronary artery disease), novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has remained stagnant for a few years. The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioactive stents, bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications. The stent market globally and in the developed nations is largely controlled by three players - Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume. This comprehensive, 465 page global strategic business report is authored by a team of sector analysts who used rigorous primary and secondary research and robust analytical models to provide strategic insight and to forecast for all major stent types BMS, DES, Bioabsorbable stents in leading 23 geographies. Data at global, continents, economic zones, and country level: - Market size of coronary stents in terms - value and volume (2005-2019) for BMS, DES and Bioabsorbables (Bioresorbable - BVS) - Market growth rates (2005-2019) - Average prices of various stents in all the covered geographies (2005-2019) - Number of PCI procedures - Analytical comparison between different continents and economic regions - Market dynamics - market trends, drivers, restrains, issues, competitive landscape - Detailed pipeline and clinical studies - Product approval status - major geographies - Industry consolidation, partnerships, product launches, approvals and recalls - Detailed company profiles of around 70 companies from different levels of value chain Key Topics Covered: 1. Charts & Tables 2. Executive Summary 3. Market at a Glance 4. Introduction to Stents 5. Coronary Stents 6. Types of Stents 7. Approvals 8. Competitive Landscape 9. Clinical Studies 10.Coronary Stents - Market Drivers and Restrains 11.Overview: Market trends 12.Approvals Driving the Growth 13. Market Data 14.Company Profiles 15.Recent Events 16.Appendix 17. Research Methodology 18. Disclaimer Companies Mentioned Include: - Abbott Vascular - Alvimedica Medical Technologies - Arterial Remodeling Technologies - Boston Scientific Corporation - Biosensors International - Biotronik SE & Co.kG - CID S.r.l. - Clearstream Technologies Ltd. - Disa Vascular (Pty) Ltd. - Elixir Medical Corporation - Endocor Gmbh - Essen Technology (Beijing) Co., Ltd - Hexacath - Iberhospitex S.A - InspireMD, Inc. - Japan Stent Technology Co., Ltd. - Kyoto Medical - Lepu Medical Technology Co., Ltd. - Medinol - Medtronic, Inc. - Meril Life Sciences Pvt. Ltd. - Micell Technologies, Inc. - MicroPort Scientific Corporation - Minvasys - OrbusNeich - Relisys Medical Devices Limited - Terumo Medical Corporation - Translumina - Tryton Medical - Vascular Concepts For more information visit http://www.researchandmarkets.com/research/3r...talysts_to
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 22, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
InspireMD to Present at the 24th Annual Oppenheimer & Co. Healthcare Conference in New York City on December 11th
PR Newswire - Tue Dec 03, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that its CEO, Alan Milinazzo will be presenting at the 24th Annual Oppenheimer & Co. Healthcare Conference at the Crowne Plaza Hotel in New York City. The Company will present at 2:45 p.m. ET on Wednesday, December 11, 2013.
InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
PR Newswire - Mon Dec 02, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced the appointment of Rick Olson as Vice President of Global Sales Operations based in the United Kingdom.
InspireMD Announces Upcoming Investor Event in Israel
PR Newswire - Tue Nov 19, 8:13AM CST
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it will host an investor event at the Dan Tel Aviv Hotel in Tel Aviv, Israel on December 2, 2013 at 5:00 p.m. local time.
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
PR Newswire - Mon Nov 11, 3:01PM CST
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for the quarter ended September 30, 2013.
InspireMD to Report Financial Results for Quarter Ending September 30, 2013 on Monday, November 11, 2013
PR Newswire - Mon Nov 04, 7:00AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the quarter ended September 30, 2013 on Monday, November 11, 2013.
InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
PR Newswire - Tue Oct 29, 3:23PM CDT
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced new 12-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients. Results from the trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco earlier today.
InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
PR Newswire - Mon Oct 28, 7:30AM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will host a conference call to discuss its MASTER trial 12-month follow up data on October 30, 2013 at 8:30 a.m. ET / 5:30 a.m. PT.
Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
PR Newswire - Fri Oct 25, 8:14AM CDT
Today Empire Asset Management Company, a FINRA member (CRD 143007), initiated coverage of INSPIRE MD (NYSE MKT: NSPR) with a Buy rating and 12 month price target of $9.00.
InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
PR Newswire - Thu Oct 24, 8:15AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced that it has secured $10 million in venture debt financing to support expanding its ability to execute on emerging clinical research and product development efforts. The Company also announced it has adopted a stockholder rights plan effective for a one year period.
InspireMD Files At-the-Market Offering and Shelf Registration Statement
PR Newswire - Thu Oct 24, 8:08AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it has filed a $75 million shelf registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC"). Once declared effective by the SEC, the shelf registration statement would permit the Company to sell, from time to time over the next three years, up to $75 million in aggregate value of its common stock, preferred stock and/or warrants, either individually or in units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
PR Newswire - Wed Oct 23, 1:43PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will ring the Opening Bell at the New York Stock Exchange on Thursday, October 24, 2013 at 9:30 a.m. ET.
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
PR Newswire - Tue Sep 17, 3:05PM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013.
InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
PR Newswire - Mon Sep 16, 7:30AM CDT
InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced the appointment of David Blossom as Vice President of Global Marketing and Strategy. Blossom will be based in Boston.
(0)
(0)InspireMD, Inc. (NSPR) Stock Research Links
Scroll down for more posts ▼